A Potential Novel Targeted Drug for the Treatment of Pulmonary Arterial Hypertension:Imatinib

VernacularTitle:潜在抗肺动脉高压新型靶向药物——伊马替尼
Author: Shanshan XIE ¹ ; Ye LI ; Lingling YU ; Jinjin WAN ; Zhiying HUANG ; Huanyu LIN ; Weifang ZHANG
Author Information

1. 南昌大学第二附属医院药学部,南昌 330006
Keywords: Imatinib; Pulmonary arterial hypertension; Novel formulations
From: Herald of Medicine 2024;43(2):262-266
CountryChina
Language:Chinese
Abstract: Pulmonary hypertension has a high mortality rate,and although targeted therapy is available,it is still incurable,and the long-term prognosis for patients is poor.As a tyrosine kinase inhibitor,imatinib was approved for marketing in China in 2002 for the treatment of chronic myelogenous leukemia and other tumor diseases.In addition to the antitumor effects,imatinib was found to improve hemodynamics and exercise tolerance in patients with severe pulmonary arterial hypertension,but the safety was suboptimal.With the emergence of new formulations of imatinib targeted at the lungs,it is expected to become a new targeted drug for pulmonary arterial hypertension.